[Cost-effectiveness of childhood vaccination against rotavirus in Norway]

Samdal K, Hagen G, Flem E, Klemp M
Record ID 32010001795
English, Norwegian
Authors' recommendations: Vaccination is an effective intervention against rotavirus gastroenteritis. However, it is also related with considerable costs. Based on study assumptions and using NOK 500 000 as threshold for cost-effective interventions, it is unlikely that routine vaccination against rotavirus will be cost-effective from a healthcare perspective (approximately 14 % and 2,5 ‰ for Rotarix® and Rotateq®, respectively). However, by adopting a societal perspective, including indirect costs due to production losses, the conclusion was changed to vaccination being considered cost-effective with a probability of approximately 94 % for Rotarix® and 4 % for Rotateq®. From a societal perspective there was also a decent probability of vaccination being deemed as cost saving to society (about 39 %). The analyses do not provide clear answers of which of the two vaccine candidates to be preferred. This must be addressed after potential bidding rounds have been completed and final vaccine prices are available.
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Norway
MeSH Terms
  • Child
  • Infant
  • Mass Vaccination
  • Norway
  • Rotavirus
  • Rotavirus Infections
  • Rotavirus Vaccines
Organisation Name: Norwegian Institute of Public Health
Contact Address: Universitetsgata 2, Postbox 7004 St. Olavs plass, NO-0310 Oslo NORWAY. Tel: +47 23 25 50 00; Fax: +47 23 25 50 10;
Contact Name: Berit.Morland@nokc.no, dagny.fredheim@nokc.no
Contact Email: Berit.Morland@nokc.no, dagny.fredheim@nokc.no
Copyright: Norwegian Knowledge Centre for the Health Services (NOKC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.